Zimmer Biomet Holdings, Inc.'s Stock Analysis

Zimmer Biomet Issues CHF 600 Million in New Bonds

Zimmer Biomet Holdings has issued two series of senior unsecured debt securities totaling CHF 600 million. This includes CHF 210 million in 0.930% Bonds maturing in 2030 and CHF 390 million in 1.560% Bonds maturing in 2035. Interest on both bonds will be paid annually, starting September 4, 2026.

The bonds include provisions for additional payments to non-U.S. holders to cover taxes, and the company may redeem the bonds under certain conditions. Holders can require the company to repurchase their bonds in case of a Change of Control Triggering Event. The bonds are subject to customary events of default and other covenants in the bond purchase agreement.

Sep 04, 2025 16:15:40

Zimmer Biomet Reports Q2 2025 Financial Results and Guidance

Zimmer Biomet Holdings, Inc. reported net sales of $2.077 billion for the second quarter of 2025, marking a 7.0% increase from the same period last year. The company also reported diluted earnings per share of $0.77, with adjusted diluted earnings per share rising by 3.0% to $2.07. The company has updated its full-year 2025 revenue growth guidance to a range of 6.7% to 7.7% and adjusted earnings per share guidance to between $8.10 and $8.30.

In addition to its financial results, Zimmer Biomet announced a definitive agreement to acquire Monogram Technologies, expanding its offerings in surgical robotics. The company has also entered a strategic partnership with Getinge to distribute operating room products to Ambulatory Surgery Center customers. Other highlights include the launch of a direct-to-patient campaign for its knee solutions and recognition as one of America’s Best Mid-Size Companies in 2025 by TIME.

Aug 07, 2025 06:30:12

Zimmer Biomet Announces Merger Agreement with Monogram Technologies

Zimmer Biomet Holdings has entered into a merger agreement with Monogram Technologies Inc., where Monogram will become a wholly-owned subsidiary of Zimmer Biomet. As part of the agreement, Monogram shareholders will receive cash payments for their shares, with common stockholders receiving $4.04 per share and preferred stockholders receiving varying amounts based on their share type. The merger is subject to regulatory approvals and the approval of Monogram's stockholders.

Investors are advised to monitor the upcoming filings with the SEC, including proxy statements related to the proposed transaction. These documents will contain important information regarding the merger, and stockholders are encouraged to read them before making any voting decisions. The merger's success may impact Zimmer Biomet's stock price and operational results, and potential risks include regulatory delays, competing offers, and integration challenges post-merger.

Jul 14, 2025 07:40:25

Company Secures $1 Billion Revolving Credit Facility Agreement

The Company has entered into a 364-Day Revolving Credit Agreement with JPMorgan Chase Bank, N.A. for an unsecured revolving credit facility valued at $1.0 billion. This facility will mature on June 26, 2026, and the funds will be utilized for general corporate purposes. Interest rates on borrowings will be based on floating rates tied to the Company's credit rating, and the agreement includes standard covenants regarding corporate financial activities.

Additionally, the Company has terminated its previous Five-Year Revolving Credit Agreement and 364-Day Revolving Credit Agreement, with no outstanding principal under the latter. At the termination date, approximately $50.7 million was owed under the previous Five-Year Credit Agreement, of which $50.0 million was repaid through the new agreement, while the remaining amount was settled with cash. Existing letters of credit from the terminated agreement have been transitioned to the new facility.

Jun 30, 2025 16:15:36

Zimmer Biomet Appoints New Group President for Americas

Zimmer Biomet Holdings, Inc. has announced the appointment of Kevin Thornal as Group President, Global Businesses and the Americas, effective July 1, 2025. He will oversee the Americas commercial organization and lead business strategy for key units including Knees, Hips, and Data Solutions. Thornal brings over 20 years of experience in the medical technology sector, having previously served as CEO of Nevro Corp. and held leadership roles at Hologic, Inc. and Stryker Corp.

Thornal is expected to contribute to Zimmer Biomet’s goals of enhancing U.S. performance and advancing its mission to improve patient quality of life. His prior success in driving growth and leading teams in the orthopedics industry positions him to address unmet needs in musculoskeletal health and support the company's new product initiatives.

May 27, 2025 07:35:29

Zimmer Biomet Reports Q1 2025 Financial Results and Guidance Update

Zimmer Biomet Holdings, Inc. announced its financial results for the first quarter of 2025, reporting net sales of $1.909 billion, which represents a 1.1% increase from the same period last year. The company recorded diluted earnings per share of $0.91, with adjusted diluted earnings per share at $1.81. The results reflect growth in the U.S. hips segment and the completion of the acquisition of Paragon 28, which is expected to enhance Zimmer Biomet’s offerings in the foot and ankle orthopedic market.

The company also updated its full-year 2025 revenue guidance to reflect the Paragon 28 acquisition and currency expectations. The revised guidance projects a reported revenue change of 5.7% to 8.2%, compared to the previous estimate of 1.0% to 3.5%. Adjusted diluted earnings per share guidance has been adjusted downwards to a range of $7.90 to $8.10 from the prior range of $8.15 to $8.35. Zimmer Biomet continues to focus on innovation and expanding its product portfolio, which includes recent FDA clearances and new marketing campaigns aimed at improving patient mobility.

May 05, 2025 06:30:09

Zimmer Biomet Completes Acquisition of Paragon 28

Zimmer Biomet Holdings, Inc. has finalized its acquisition of Paragon 28, Inc., a company specializing in foot and ankle orthopedic devices. This acquisition is expected to enhance Zimmer Biomet's offerings in the rapidly growing foot and ankle segment and will leverage Paragon 28's specialized sales organization to create a dedicated sales channel within Zimmer Biomet. The deal is anticipated to drive innovation and growth in both U.S. and international markets.

As part of the acquisition, each outstanding common share of Paragon 28 was converted into $13.00 in cash and a contingent value right that may provide up to an additional $1.00 per share if certain revenue milestones are met. Following the completion of the acquisition on April 21, 2025, Paragon 28 has become a wholly-owned subsidiary of Zimmer Biomet, and its shares will no longer be traded on the New York Stock Exchange.

Apr 21, 2025 16:05:14

Zimmer Biomet Board Changes Include Chairman and Lead Director Appointments

Zimmer Biomet Holdings, Inc. announced significant changes to its Board of Directors, including the retirement of Non-Executive Chairman Christopher Begley, effective May 29, 2025, due to the mandatory retirement age. President and CEO Ivan Tornos will succeed him as Chairman, while Michael Farrell will take on the role of Lead Independent Director. Begley has been with the Board since 2012 and has played a crucial role in the company's development during his tenure.

The transition in leadership is highlighted by Tornos' promotion, which reflects confidence in his ability to enhance value for stakeholders. Farrell, who has been a Board member since 2014 and is currently CEO of ResMed Inc., is also recognized for his leadership qualities. The company emphasizes its commitment to innovation and improving patient experiences through its medical technology offerings.

Feb 25, 2025 16:14:44

Company Announces New Notes with Specific Interest Rates and Terms

The company has launched a new offering of Notes with varying interest rates: 4.700% for 2027 Notes, 5.050% for 2030 Notes, and 5.500% for 2035 Notes, payable semi-annually starting August 19, 2025. The Notes have specific maturity dates ranging from 2027 to 2035, and the company has the option to redeem them under certain conditions. Additionally, the company is set to acquire Paragon 28 through a merger, which could trigger mandatory redemption for the 2030 and 2035 Notes if the merger does not close by specified dates or is terminated. The 2027 Notes are exempt from this mandatory redemption requirement and will remain outstanding regardless of the merger outcome. 

On the negative side, the company faces potential financial obligations if the merger with Paragon 28 is not completed by the deadlines outlined, which may lead to a special mandatory redemption of the 2030 and 2035 Notes. The offering also includes customary events of default, such as nonpayment and failure to comply with covenants, which could pose risks to the company’s financial stability. The complexities surrounding the merger and the redemption clauses may create uncertainty for investors in the Notes.

Feb 19, 2025 16:16:42

Zimmer Biomet Reports $7.679 Billion in Full-Year Sales

Zimmer Biomet announced its fourth quarter and full-year 2024 financial results, highlighting a 4.3% increase in fourth quarter net sales to $2.023 billion, and a full-year net sales increase of 3.8% to $7.679 billion. The company also reported diluted earnings per share of $1.20 for the fourth quarter and $4.43 for the full year, with adjusted diluted earnings per share of $2.31 and $8.00, respectively. Additionally, the company is diversifying its portfolio with the planned acquisition of Paragon 28, aimed at expanding into the foot and ankle orthopedic segment, which is valued at approximately $5 billion.

On the downside, the company faced a decline in sales within its Technology & Data, Bone Cement, and Surgical category, which saw a 4.9% decrease in the fourth quarter. Furthermore, Zimmer Biomet's Hips product category experienced a modest growth of only 1.6% for the full year, indicating potential challenges in this segment. The company also mentioned various risks associated with the acquisition and integration of Paragon 28, including regulatory approvals and operational disruptions, which could impact the expected benefits from this strategic move.

Feb 06, 2025 06:30:10